development
Cancer Market Commentary: Keytruda’s triumph not the last word in NSCLC
Andrew McConaghie
2016, cancer, development, ESMO, Keytruda, Opdivo, pharma, treatment
0 Comment
Despite Keytruda’s overwhelming victory, it’s not over yet in NSCLC
X
Cancer Market Commentary: Keytruda’s triumph not the last word in NSCLC
https://pharmaphorum.com/esmo-2016/keytruda-triumph-esmo/